The European Vision Institute EEIG
European Alliance for the Promotion of Vision Research and Ophthalmology
Blindness is one of the most feared health hazards in our present society; millions of Europeans are threatened by blinding untreatable eye diseases producing costs of several billion Euros. EVI aims at devising and implementing programs and projects for new therapeutic strategies for eye diseases that are difficult or impossible to be treated presently. Its approach will incorporate the most recent scientific developments of the postgenomic area.
The Importance of EVI
The European Vision Institute should be of enormous strategic importance for the future and is targeted towards more immediate policy objectives of improving the competitiveness of European Research assembling the top institutes together with partners from industry and academia. EVI integrates, conducts and supports research that helps to prevent and treat eye diseases and other disorders of vision. This research leads to sight-saving treatments, reduces visual impairment and blindness, and improves the quality of life for people of all ages.
Nightstar receives U.S. and European Orphan Drug Designation for gene therapy to treat Choroideremia
April 17, 2015
NightstaRx Ltd ("Nightstar"), the biopharmaceutical company specialising in bringing therapies for...
April 15, 2015
Council agrees negotiating stance on European fund for strategic investments
April 13, 2015
When ICT and ART connect
April 09, 2015
The 7th European Innovation Summit (7th EIS) is Knowledge4Innovation's annual flagship event taking...
The "Gateway to European Vision Research" is a web-based portal service for the European vision research community and major stakeholders.
The Vision Awards
An award and public recognition by any measure is a sign of inimitability - an acknowledgment that peers and professionals alike agree that a certain person excels in what they do.
Read more about the European Vision Award and the Carl Zeiss Young Investigator Award.